NEWS & MEDIA

TAKOMA PARK, Md.--(BUSINESS WIRE)--US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery. The CHCP system consists of the...

TAKOMA PARK, Md.--(BUSINESS WIRE)--The Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) and US Medical Innovations, LLC (USMI) are pleased to announce today a ground-breaking achievement in surgical and robotic...

The First Cold Atmospheric Plasma Phase 1 Clinical Trial for the Treatment of Advanced Solid Tumors: A Novel Treatment Arm for Cancer TAKOMA PARK, Md.--(BUSINESS WIRE)--The Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI) and...

TAKOMA PARK, Md.--(BUSINESS WIRE)--US Medical Innovations, LLC (USMI), a Biomedical and Life Science subsidiary of US Patent Innovations, LLC, announced today it has received FDA Approval for its Canady Flex RoboWrist™ to be used in open and laparoscopic procedures in...

TAKOMA PARK, Md.--(BUSINESS WIRE)—June 15, 2023 - The Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) and US Medical Innovations, LLC (USMI) announced significant positive results from the first FDA Phase I IDE...

TAKOMA PARK, Md.--(BUSINESS WIRE)--US Medical Innovations, LLC (USMI), a subsidiary of US Patent Innovations, LLC, announced today it has secured a $10.2 million private placement deal from multiple sources including existing partners and new investors. USMI will be...

TAKOMA PARK, Md.--(BUSINESS WIRE)--Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) and US Medical Innovations, LLC (USMI) announced today that Jerome Canady MD, Chief Science Officer at JCRI-ABTS and a Surgical...

TAKOMA PARK, Md.--(BUSINESS WIRE)--The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), announced today that their recent article, BCL2A1 REGULATES CANADY HELIOS COLD PLASMA-INDUCED CELL DEATH IN TRIPLE-NEGATIVE BREAST...

TAKOMA PARK, Md.--(BUSINESS WIRE)--US Medical Innovations, LLC (USMI) and the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) announced today that the United States Patent and Trademark Office has issued a Notice of...

TAKOMA PARK, Md.--(BUSINESS WIRE)--US Medical Innovations, LLC (USMI), a U.S. FDA-registered life-science and biomedical device company and the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) announced today that Jerome...

Jerome Canady, Saravana R. K. Murthy, Taisen Zhuang, Steven Gitelis, Aviram Nissan, Lawan Ly, Olivia Z. Jones, Xiaoqian Cheng, Mohammad Adileh, Alan T. Blank, Matthew W. Colman, Kieth Millikan, Cristina O’Donoghue, Kerstin M. Stenson, Karen Ohara, Gal Schtrechman,...

Lawan Ly, Xiaoqian Cheng, Saravana R. K. Murthy, Olivia Z. Jones, Taisen Zhuang, Steven Gitelis, Alan T. Blank, Aviram Nissan, Mohammad Adileh, Matthew Colman, Michael Keidar, Giacomo Basadonna and Jerome Canady Soft tissue sarcomas (STS) are a rare and highly...

Annisa Elbedour, Xiaoqian Cheng, Saravana R. K. Murthy, Taisen Zhuang, Lawan Ly, Olivia Jones, Giacomo Basadonna, Michael Keidar, and Jerome CanadyCold atmospheric plasma (CAP) has become a promising tool for modern medicine. With its recent applications in oncology,...

Saravana R. K. Murthy, Xiaoqian Cheng, Taisen Zhuang, Lawan Ly, Olivia Jones, Giacomo Basadonna, Michael Keidar, & Jerome CanadyBreast cancer is the most common cause of cancer death among women worldwide1 and it exhibits diverse molecular features that reflect the...

Cold atmospheric plasma is a promising adjuvant therapy to selectively combat many cancers, including breast cancer, but not normal tissue; however, the underlying mechanisms remain unexplored. Here, four breast cancer cell lines with different marker status were treated with Canady Helios Cold Plasma™ (CHCP) at various dosages and their differential progress of apoptosis was monitored. Inhibition of cell proliferation, induction of apoptosis, and disruption of the cell cycle were observed. At least 16 histone mRNA types were oxidized and degraded immediately after CHCP treatment by 8-oxoguanine (8-oxoG) modification.

Cold atmospheric plasma (CAP) has been extensively studied in various biomedical fields. It is a novel approach to targeted cancer treatment and has demonstrated its anti-cancer effects in vitro. The detailed mechanism have not been fully elucidated, however studies have established that CAP selectively induces apoptosis and DNA damage in tumor cells.

Xiaoqian Cheng, Saravana R. K. Murthy, Taisen Zhuang, Lawan Ly, Olivia Jones, Giacomo Basadonna, Michael Keidar, Yasmine Kanaan, and Jerome CanadyBreast cancer is a heterogenous disease which can be classified into subtypes by the presence or absence of estrogen...

Mark Peplow PhDWhen a surgeon removes a tumor, some cancer cells may get left behind, threatening to seed another malignant growth. Researchers have just begun the first clinical trial of a new anticancer tool that they hope will kill these stubborn cells: a plasma...

Connor J. Wakefield, BS, Chris Culvern, MS, Matthew W. Colman, MD, Jerome Canady, MD, Steven Gitelis, MD, Alan T. Blank, MD, MSAs medicine continues to seek increasingly improved outcomes, many fields have developed novel and innovative treatments. The field of...

Lawan Ly, Sterlyn Jones, Alexey Shashurin, Taisen Zhuang, Warren Rowe III, Xiaoqian Cheng, Shruti Wigh, Tammey Naab, Michael Keidar, and Jerome CanadyElectrosurgery is the use of high frequency radiofrequency (RF) alternating current (AC) for cutting and coagulation...